Clinical Trial Update: MR Antagonist and LSD1 [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating a mineralocorticoid receptor antagonist in combination with an LSD1 inhibitor for hypertension and mineralocorticoid excess; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Mineralocorticoid Excess

Drugs mentioned

• LSD1 inhibitor (Lysine-specific demethylase 1 inhibitor)
• Mineralocorticoid receptor antagonist (Mineralocorticoid receptor antagonist)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Hypertension, Mineralocorticoid Excess | Phase 4 | Status: ACTIVE_NOT_RECRUITING